Literature DB >> 11510689

Wild type p73 overexpression and high-grade malignancy in breast cancer.

G Dominguez1, J M Silva, J Silva, J M Garcia, A Sanchez, A Navarro, I Gallego, M Provencio, P España, F Bonilla.   

Abstract

The overexpression of wild type p73 is the most frequent alteration of p73 in malignancies. We investigated, in 70 breast carcinomas, p73 mRNA expression and its relationship to p53 mutations, determined by an immunohistochemical method, and loss heterozygosity (LOH) status of the 1p36 region, together with its possible implication in the pathogenesis of breast carcinomas. LOH, amplifying DNA by PCR using 5 markers, of 1p36 region (one intragenic to p73 gene) was found in 17% of cases but no significant correlation was observed with p73 overexpression. p53 positive immunostaining was present in 33% of breast carcinomas, and these exhibited a statistically significant relation with p73 overexpressed tumors. Overexpression of p73 mRNA was observed in 19 tumors (27%). The analysis of cases with p73 overexpression and cases with normal mRNA expression, in terms of age and pathologic characteristics of the tumors showed a significant association of p73 overexpression and tumors with lymph node metastases, vascular invasion and higher pathologic stage. These results suggest that p73 overexpression is a molecular alteration that could be implicated in the tumorigenesis of breast carcinomas and, eventually, in a poor clinical behavior.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11510689     DOI: 10.1023/a:1010624717311

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  18 in total

Review 1.  Regulation of breast cancer metastasis signaling by miRNAs.

Authors:  Belinda J Petri; Carolyn M Klinge
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

2.  BRD4 drives esophageal squamous cell carcinoma growth by promoting RCC2 expression.

Authors:  Qiong Wu; Fangfang Liu; Mengmeng Ge; Kyle Vaughn Laster; Lixiao Wei; Ruijuan Du; Ming Jiang; Jing Zhang; Yafei Zhi; Guoguo Jin; Simin Zhao; Dong Joon Kim; Zigang Dong; Kangdong Liu
Journal:  Oncogene       Date:  2021-11-08       Impact factor: 9.867

3.  The expression of p73, p21 and MDM2 proteins in gliomas.

Authors:  Makoto Kamiya; Yoichi Nakazato
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

4.  A gene signature-based approach identifies mTOR as a regulator of p73.

Authors:  Jennifer M Rosenbluth; Deborah J Mays; Maria F Pino; Luo Jia Tang; Jennifer A Pietenpol
Journal:  Mol Cell Biol       Date:  2008-08-04       Impact factor: 4.272

5.  The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers.

Authors:  Chee-Onn Leong; Nick Vidnovic; Maurice Phillip DeYoung; Dennis Sgroi; Leif W Ellisen
Journal:  J Clin Invest       Date:  2007-04-19       Impact factor: 14.808

Review 6.  The p53 pathway in breast cancer.

Authors:  Milena Gasco; Shukri Shami; Tim Crook
Journal:  Breast Cancer Res       Date:  2002-02-12       Impact factor: 6.466

Review 7.  p53 Family and Cellular Stress Responses in Cancer.

Authors:  Johanna Pflaum; Sophie Schlosser; Martina Müller
Journal:  Front Oncol       Date:  2014-10-21       Impact factor: 6.244

8.  p73, like its p53 homolog, shows preference for inverted repeats forming cruciforms.

Authors:  Jana Čechová; Jan Coufal; Eva B Jagelská; Miroslav Fojta; Václav Brázda
Journal:  PLoS One       Date:  2018-04-18       Impact factor: 3.240

9.  Identification and functional annotation of genome-wide ER-regulated genes in breast cancer based on ChIP-Seq data.

Authors:  Min Ding; Haiyun Wang; Jiajia Chen; Bairong Shen; Zhonghua Xu
Journal:  Comput Math Methods Med       Date:  2012-12-31       Impact factor: 2.238

10.  p53 inactivation upregulates p73 expression through E2F-1 mediated transcription.

Authors:  Chaitali Tophkhane; Shi-He Yang; Yunbo Jiang; Zhikun Ma; Dharmalingam Subramaniam; Shrikant Anant; Shingo Yogosawa; Toshiyuki Sakai; Wan-Guo Liu; Susan Edgerton; Ann Thor; Xiaohe Yang
Journal:  PLoS One       Date:  2012-08-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.